Statin Use Is Associated With a Lower Risk of Blepharitis: A Population-Based Study.
HMG-CoA
blepharitis
cohort-study
meibomian gland dysfunction (MGD)
statin
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2022
2022
Historique:
received:
22
11
2021
accepted:
14
02
2022
entrez:
4
4
2022
pubmed:
5
4
2022
medline:
5
4
2022
Statut:
epublish
Résumé
Blepharitis is a common eye disorder that may be overlooked by patients and clinical practitioners. The symptoms of blepharitis often manifest as irritation, a burning sensation, grittiness, and itchiness and may decrease visual acuity if not treated promptly. Meibomian gland dysfunction (MGD), a common cause of blepharitis, is believed to be associated with increased inflammatory marker levels that may disrupt the composition of lipids produced by the sebaceous glands in the eyelids and ultimately cause tear film instability. This is a retrospective, population-based study using National Health Insurance Research Database (NHIRD) data from a 14-year period (2000-2015). Pearson chi-squared and Student's A total of 67,014 patients who used statins were enrolled as the study cohort, and 268,056 patients who did not use statins were enrolled as the comparison cohort. The incidence of blepharitis was 3.04% with statin treatment and 3.72% without statin treatment ( Statin use can decrease the risk of developing blepharitis. However, further prospective studies are needed to evaluate statin treatment for various subtypes of blepharitis and to identify the associated mechanism.
Sections du résumé
Background
UNASSIGNED
Blepharitis is a common eye disorder that may be overlooked by patients and clinical practitioners. The symptoms of blepharitis often manifest as irritation, a burning sensation, grittiness, and itchiness and may decrease visual acuity if not treated promptly. Meibomian gland dysfunction (MGD), a common cause of blepharitis, is believed to be associated with increased inflammatory marker levels that may disrupt the composition of lipids produced by the sebaceous glands in the eyelids and ultimately cause tear film instability.
Methods
UNASSIGNED
This is a retrospective, population-based study using National Health Insurance Research Database (NHIRD) data from a 14-year period (2000-2015). Pearson chi-squared and Student's
Results
UNASSIGNED
A total of 67,014 patients who used statins were enrolled as the study cohort, and 268,056 patients who did not use statins were enrolled as the comparison cohort. The incidence of blepharitis was 3.04% with statin treatment and 3.72% without statin treatment (
Conclusion
UNASSIGNED
Statin use can decrease the risk of developing blepharitis. However, further prospective studies are needed to evaluate statin treatment for various subtypes of blepharitis and to identify the associated mechanism.
Identifiants
pubmed: 35372440
doi: 10.3389/fmed.2022.820119
pmc: PMC8965040
doi:
Types de publication
Journal Article
Langues
eng
Pagination
820119Informations de copyright
Copyright © 2022 Feng, Chung, Chen, Chien and Chien.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Expert Rev Ophthalmol. 2010 Aug 1;5(4):557-577
pubmed: 21760834
Invest Ophthalmol Vis Sci. 2011 Mar 30;52(4):1922-9
pubmed: 21450913
Case Rep Ophthalmol. 2020 Jun 9;11(2):212-216
pubmed: 32595485
Med Clin North Am. 2012 Mar;96(2):269-81
pubmed: 22443975
Ophthalmology. 2019 Jan;126(1):P56-P93
pubmed: 30366800
Curr Opin Ophthalmol. 2011 Sep;22(5):385-90
pubmed: 21730841
Ophthalmology. 2011 Jun;118(6):1062-8
pubmed: 21276617
Eur J Epidemiol. 2021 Mar;36(3):335-344
pubmed: 33548002
Diabet Med. 2006 Apr;23(4):393-7
pubmed: 16620267
Am J Ophthalmol. 2020 Nov;219:240-252
pubmed: 32621892
BMC Ophthalmol. 2018 Apr 12;18(1):90
pubmed: 29649988
Am J Pathol. 2005 Jan;166(1):61-71
pubmed: 15632000
Curr Eye Res. 2015 Feb;40(2):162-75
pubmed: 25290221
Clin Exp Ophthalmol. 2019 Mar;47(2):187-192
pubmed: 30203595
Semin Ophthalmol. 2010 May;25(3):79-83
pubmed: 20590417
Ocul Surf. 2009 Apr;7(2 Suppl):S1-S14
pubmed: 19383269
Br J Ophthalmol. 2018 Sep;102(9):1283-1287
pubmed: 29146760
Cornea. 1992 Jul;11(4):334-42
pubmed: 1424655
Graefes Arch Clin Exp Ophthalmol. 2019 Apr;257(4):785-790
pubmed: 30666404
Exp Eye Res. 2013 Dec;117:4-27
pubmed: 23769846
Invest Ophthalmol Vis Sci. 2009 Aug;50(8):3671-9
pubmed: 19324847
Ophthalmic Res. 2008 Oct;40(6):315-21
pubmed: 18688174
PLoS One. 2013 Dec 30;8(12):e83335
pubmed: 24386181
Clin Exp Ophthalmol. 2017 Jul;45(5):448-454
pubmed: 28183148
Invest Ophthalmol Vis Sci. 2013 Feb 15;54(2):1352-60
pubmed: 23341008
Int J Inflam. 2013;2013:434586
pubmed: 24159421
Int Ophthalmol. 2020 Nov;40(11):3049-3058
pubmed: 32601963
Prog Neurobiol. 2008 May;85(1):1-74
pubmed: 18346832
Horm Metab Res. 1983 Sep;15(9):449-52
pubmed: 6642415
Nat Rev Drug Discov. 2005 Dec;4(12):977-87
pubmed: 16341063
Ophthalmic Res. 2015;54(1):26-33
pubmed: 26068735
Cochrane Database Syst Rev. 2012 May 16;(5):CD005556
pubmed: 22592706
J Ophthalmol. 2012;2012:285851
pubmed: 23050121
Surv Ophthalmol. 2019 May - Jun;64(3):401-432
pubmed: 30703407
Ophthalmology. 1994 Jun;101(6):1118-21
pubmed: 8008353
Ophthalmology. 2013 Dec;120(12):2385-2389
pubmed: 23747164
J Cell Mol Med. 2001 Oct-Dec;5(4):378-87
pubmed: 12067471